From combinatorial peptide selection to drug prototype (I): Targeting the vascular endothelial growth factor receptor pathway
暂无分享,去创建一个
Wadih Arap | Renata Pasqualini | R. Sidman | W. Arap | F. Almeida | A. Valente | D. Hawke | M. Cardó-Vila | R. Pasqualini | A. Salameh | J. Nör | David H Hawke | Marina Cardó-Vila | Richard L Sidman | R. Giordano | Ricardo J Giordano | Jacques E Nör | C. D. Anobom | Ahmad Salameh | Cristiane D Anobom | Benjamin D Zeitlin | Ana P Valente | Fábio C L Almeida | B. Zeitlin
[1] M. Chorev. The partial retro–inverso modification: A road traveled together , 2005, Biopolymers.
[2] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.
[3] A. Passaniti,et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. , 1992, Laboratory investigation; a journal of technical methods and pathology.
[4] Wadih Arap,et al. Biopanning and rapid analysis of selective interactive ligands , 2001, Nature Medicine.
[5] Michael I Dorrell,et al. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis , 2007, Proceedings of the National Academy of Sciences.
[6] M. Giacca,et al. Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.
[7] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[8] Vladimir Sklenar,et al. Gradient-Tailored Water Suppression for 1H-15N HSQC Experiments Optimized to Retain Full Sensitivity , 1993 .
[9] R. Sidman,et al. Spare the rod and spoil the eye , 2005, British Journal of Ophthalmology.
[10] E. Marinelli,et al. Tuftsin Binds Neuropilin-1 through a Sequence Similar to That Encoded by Exon 8 of Vascular Endothelial Growth Factor* , 2006, Journal of Biological Chemistry.
[11] A. Pini,et al. Bioactive peptides from libraries. , 2005, Chemistry & biology.
[12] C. Lilley,et al. A Hybrid Vector for Ligand-Directed Tumor Targeting and Molecular Imaging , 2006, Cell.
[13] L. Ellis,et al. VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.
[14] Christoph Dehio,et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.
[15] P. Carmeliet,et al. Development of targeted angiogenic medicine , 2009, Journal of thrombosis and haemostasis : JTH.
[16] L. Ellis,et al. Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy , 2008, Clinical Cancer Research.
[17] K. Alitalo,et al. Molecular regulation of angiogenesis and lymphangiogenesis , 2007, Nature Reviews Molecular Cell Biology.
[18] E. Ruoslahti,et al. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration , 2009, Proceedings of the National Academy of Sciences.
[19] David J Mooney,et al. Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice , 2001, Laboratory Investigation.
[20] J. Folkman. Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.
[21] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[22] D. Hicklin,et al. Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer , 2006, Clinical Cancer Research.
[23] Lois E. H. Smith,et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] W. Arap,et al. Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. , 2005, Chemistry & biology.
[25] Franklin Peale,et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. , 2007, Cancer cell.
[26] K. Becker,et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis , 2009, Proceedings of the National Academy of Sciences.
[27] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[28] A. Luttun,et al. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets? , 2004, Biochimica et biophysica acta.
[29] S. Ross,et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. , 2007, Cancer research.
[30] R. Sidman,et al. An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[31] Lois E. H. Smith,et al. Retinopathy of Prematurity: Current Concepts in Molecular Pathogenesis , 2009, Seminars in ophthalmology.
[32] P. Fischer,et al. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. , 2003, Current protein & peptide science.
[33] F. Peale,et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies , 2007, Proceedings of the National Academy of Sciences.
[34] Lena Claesson-Welsh,et al. Orf virus VEGF‐E NZ2 promotes paracellular NRP‐1/VEGFR‐2 coreceptor assembly via the peptide RPPR , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] Lois E. H. Smith,et al. Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.
[36] M. Crépin,et al. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. , 2006, Life sciences.
[37] Till Acker,et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.
[38] Christian Fischer,et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.
[39] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[40] Peter Carmeliet,et al. Angiogenesis in life, disease and medicine , 2005, Nature.
[41] A. Luttun,et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.
[42] W. Arap,et al. Display technologies: Application for the discovery of drug and gene delivery agents , 2006, Advanced Drug Delivery Reviews.
[43] R. Jaenisch. Stem cells, pluripotency and nuclear reprogramming , 2009, Journal of thrombosis and haemostasis : JTH.
[44] N. Ferrara,et al. VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.
[45] Yihai Cao,et al. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1 , 1998, Oncogene.
[46] G. Noronha,et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. , 2008, The Journal of clinical investigation.